United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,241 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up $3.33 during mid-day trading on Friday, reaching $133.32. 342,729 shares of the company traded hands, compared to its average volume of 558,225. United Therapeutics Corporation has a 52 week low of $112.01 and a 52 week high of $169.89. The stock has a market capitalization of $5,760.00, a PE ratio of 10.98 and a beta of 1.38.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The company had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter last year, the company posted $4.23 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. equities research analysts expect that United Therapeutics Corporation will post 12.29 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of UTHR. HPM Partners LLC raised its position in United Therapeutics by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 15 shares during the period. First Allied Advisory Services Inc. raised its position in United Therapeutics by 0.4% in the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after acquiring an additional 19 shares during the period. Synovus Financial Corp raised its position in United Therapeutics by 1.2% in the second quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after acquiring an additional 69 shares during the period. Ifrah Financial Services Inc. raised its position in United Therapeutics by 1.7% in the second quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 76 shares during the period. Finally, Alps Advisors Inc. raised its position in United Therapeutics by 2.3% in the second quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock worth $496,000 after acquiring an additional 86 shares during the period. Institutional investors own 99.83% of the company’s stock.

UTHR has been the topic of a number of recent analyst reports. ValuEngine cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 8th. Zacks Investment Research upgraded shares of United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Oppenheimer restated a “buy” rating on shares of United Therapeutics in a report on Friday, September 8th. Cowen restated a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a report on Friday, October 27th. Finally, HC Wainwright restated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $136.10.

ILLEGAL ACTIVITY NOTICE: “United Therapeutics Corporation (UTHR) CEO Sells $160,026.95 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/united-therapeutics-corporation-uthr-ceo-sells-160026-95-in-stock.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.